INT J LAB HEMATOL:通过双色荧光实时PCR同时检测白血病中的45个融合基因

2017-04-20 MedSci MedSci原创

研究人员开发了一种新型双色TaqMan探针实时PCR方法,可同时在12个平行反应中筛选45个融合转录本。该方法用携带已知融合转录物和患者样品的细胞系进行测试和验证。

近日,国际杂志INT J LAB HEMATOL上在线发表一篇关于通过双色荧光实时PCR同时检测白血病中的45个融合基因的研究。

复发性遗传异常的检测对于白血病预后的精确诊断和评估具有重要意义。然而传统的嵌套逆转录PCR费时费力。

研究人员开发了一种新型双色TaqMan探针实时PCR方法,可同时在12个平行反应中筛选45个融合转录本。该方法用携带已知融合转录物和患者样品的细胞系进行测试和验证。

研究人员成功开发了用于快速检测45个融合基因,并验证了15种更常见的融合基因的多重实时PCR方法。批内最频繁重排的测定重现性在循环阈值(Ct)的变异系数(CV)为0.41%至0.74%,并且在5个单独实验中的批次间重现性范围为1.62%至2.83%。测试的易位检测限最低在116 000132 000之间。对213例患者样本的验证显示出100%的特异性,且与常规巢式RT-PCR一致性较高。

总的来说,研究认为,这种方法易于应用,成本效益好,临床上可用于在白血病初期诊断阶段快速筛选融合基因。其使用也可以扩展到监测微小残留疾病。

原始出处:

Z. Zheng, P. Zhang, G. He, K. et.al. Simultaneous detection of 45 fusion genes in leukemia by dual-color fluorescence real-time PCR (pages 175–184): 30 JAN 2017 | DOI: 10.1111/ijlh.12600

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1707763, encodeId=0edd1e07763e4, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Sat Feb 24 14:00:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317276, encodeId=64be131e27647, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419386, encodeId=75cb141938646, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525435, encodeId=fc801525435f4, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542625, encodeId=57dd154262594, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1707763, encodeId=0edd1e07763e4, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Sat Feb 24 14:00:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317276, encodeId=64be131e27647, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419386, encodeId=75cb141938646, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525435, encodeId=fc801525435f4, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542625, encodeId=57dd154262594, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-21 fengyi812
  3. [GetPortalCommentsPageByObjectIdResponse(id=1707763, encodeId=0edd1e07763e4, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Sat Feb 24 14:00:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317276, encodeId=64be131e27647, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419386, encodeId=75cb141938646, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525435, encodeId=fc801525435f4, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542625, encodeId=57dd154262594, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-21 Tommy1950
  4. [GetPortalCommentsPageByObjectIdResponse(id=1707763, encodeId=0edd1e07763e4, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Sat Feb 24 14:00:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317276, encodeId=64be131e27647, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419386, encodeId=75cb141938646, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525435, encodeId=fc801525435f4, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542625, encodeId=57dd154262594, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-21 licz0427
  5. [GetPortalCommentsPageByObjectIdResponse(id=1707763, encodeId=0edd1e07763e4, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Sat Feb 24 14:00:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317276, encodeId=64be131e27647, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419386, encodeId=75cb141938646, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525435, encodeId=fc801525435f4, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542625, encodeId=57dd154262594, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Fri Apr 21 15:00:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]

相关资讯

PLoS One:RPA技术在艾滋病检测中大展身手

重组酶聚合酶扩增RPA被称为是可以替代PCR的核酸检测技术。RPA扩增的速度非常快,灵敏度高,对硬件设备要求低,而且不需要复杂的样本处理。这样的技术特别适合于体外诊断、兽医、食品安全、生物防御、农业等领域。 在艾滋病诊治中,即时检测是非常重要的,对婴儿来说更是如此。有案例显示,艾滋病毒(HIV)感染后立刻进行治疗就能控制住患者体内的病毒,让它们无法进行复制。举例来说,生来就携带HIV

核酸检测的一场革命,可替代PCR的犀利技术

  自PCR技术诞生以来已经有三十年了。从经典PCR、实时定量PCR再到现在的数字PCR,这一技术在不断蜕变却从未淡出我们的视野。 英国TwistDx Inc公司开发的重组酶聚合酶扩增(Recombinase Polymerase Amplification,RPA),被称为是可以替代PCR的核酸检测技术。以此为基础的TwistAmp® 核酸扩增产品,能够在15分钟内进行常温下的

ALLERGY:成人和儿童嗜酸粒细胞性食管炎中嗜酸性粒细胞分子谱差异性研究

嗜酸粒细胞性食管炎(EoE)可影响儿童和成人。儿童和成人EoE是否为不同的病种一直都有争议。本研究目的即探讨儿童EoE的血嗜酸性粒细胞分子模式是:1)与健康儿童不同; 2)与成人EoE不同。

J Pediatr:PCR检测新生儿单纯疱疹病毒感染

J Pediatr近日发布的一项研究表明,新生儿单纯疱疹病毒(herpes simplex virus,HSV)疾病的临床表现和死亡率有关,但是与神经系疾病没有相关性为了评估单疱病毒qPCR检测判断新生儿HSV疾病预后的效果,西雅图儿童研究机构儿童感染科的Ann J. Melvin医生及其同事对1993-2012年在西雅图儿童医院治疗的HSV感染新生儿的临床和病毒数据进行研究。研究共纳入了63名婴

Thorax:16S PCR可以快速确诊呼吸机相关肺炎

本研究衍生出了一种新型应用的16S PCR,并对其诊断的准确性进行了评估。这表明通过16S PCR检测支气管肺泡灌洗可作为疑似呼吸机相关肺炎的快速检测方法,以便更好地管理抗生素的使用。

乳腺癌新辅助化疗评估终点(pCR/RCB)的合理应用

乳腺癌新辅助化疗是乳腺癌的术前化疗,为非解救性化疗,其适应证为:   ①使不可手术的乳腺癌变为可手术乳腺癌;   ②使不可保乳的乳腺癌转为可保乳;   ③获得体内的药物敏感性信息;   ④评价药物临床试验的终点指标,加速新型药物的研发和审批。施行新辅助化疗,是为预期手术还是争取病理性完全缓解(pathologic